O

Ocugen
D

OCGN

0.66960
USD
-0.02
(-3.38%)
مغلق
حجم التداول
44,079
الربح لكل سهم
-0
العائد الربحي
-
P/E
-3
حجم السوق
195,532,889
أصول ذات صلة
A
ABUS
-0.07000
(-2.13%)
3.22000 USD
A
ALT
-0.22000
(-3.80%)
5.57500 USD
A
AUPH
-0.11500
(-1.42%)
7.98500 USD
BNTX
BNTX
-1.880
(-1.99%)
92.820 USD
I
INO
-0.01500
(-0.83%)
1.80000 USD
MRNA
MRNA
-0.320
(-1.30%)
24.250 USD
N
NVAX
-0.67000
(-10.08%)
5.97500 USD
V
VIR
-0.31500
(-5.83%)
5.08500 USD
V
VXRT
0.01670
(4.14%)
0.41980 USD
المزيد
الأخبار المقالات

العنوان: Ocugen

القطاع: Healthcare
الصناعة: Biotechnology
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").